Comments
Lupin has received approval from the US health regulator for its Suprax oral suspension used for treating bacterial infections and expects to commence shipping the product in the near future.
The company’s subsidiary Lupin Pharmaceuticals Inc. has received approval for Suprax oral suspension in the strength of 500mg/5ml from the United States Food and Drugs Administration (USFDA), Lupin said in a statement today.
“Suprax is currently available as 100 mg/5ml and 200 mg/5ml suspensions, 400 mg tablets as well as chewable tablets 100 & 200 mg,” the company said.
Commenting on the approval, Lupin Group President & Lupin Pharmaceutical Inc. CEO Vinita Gupta said: “The new dosage form will add to our growing Suprax franchise and gives healthcare providers and patients a new formulation to treat the indicated infections.”
“This new drug application provides for a new strength 500 mg/5ml of Suprax (cefixime) for the treatment of otitis media, acute exacerbation of chronic bronchitis, uncomplicated urinary tract infections (cervical/urethral), uncomplicated gonorrhoea and pharyngitis/tonsillitis,” the company said.
Shares of Lupin Ltd were today trading at Rs 599.85 per scrip on BSE, up 0.98 per cent from their previous close.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.